Breast cancer
Conditions
Interventions
Etomidate-propofol group:Anesthesia induction: intravenous administration of a 2:3 mixture of etomidate and propofol at 0.2 mL/kg
Anesthesia maintenance: intravenous infusion of a 2:3 mixture of etomi
Remimazolam group:Anesthesia induction: intravenous administration of remimazolam besylate 0.3 mg/kg
Anesthesia maintenance: intravenous infusion of remimazolam besylate 0.4-1.2 mg/(kg·h)
Sponsors
The First Affiliated Hospital of Anhui University of Science and Technology
Eligibility
Sex/Gender
Female
Age
60 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with primary breast cancer by pathological diagnosis and undergoing radical mastectomy at a scheduled time, with TNM stage I-II; 2. Age 60-75 years old; 3. ASA grade II-IV; 4. Body mass index (BMI) 22-28 kg/m^2; 5. Participate voluntarily and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with severe cerebrovascular disease, craniocerebral trauma, etc. that affect cognitive function assessment; 2. Patients with a history of mental disorders and taking sedatives, hypnotic drugs and psychotropic drugs in the past six months; 3. Patients with severe heart, lung, liver, kidney and metabolic diseases that cause intolerance to general anesthesia surgery; 4. Patients with allergic reaction to any component of the experimental drug; 5. Patients with adrenal cortex insufficiency; 6. Operation time > 3.5 hours; 7. Blood transfusion during operation; 8. Intraoperative bleeding > 500ml.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Postoperative pain;Cognitive function;Postoperative adverse reactions; | — |
Secondary
| Measure | Time frame |
|---|---|
| Intraoperative vital signs;Wake-up quality; | — |
Countries
China
Contacts
Public ContactShi Jun
The First Affiliated Hospital of Anhui University of Science and Technology
Outcome results
None listed